Compare WYY & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WYY | TTRX |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.8M | 107.2M |
| IPO Year | 2005 | N/A |
| Metric | WYY | TTRX |
|---|---|---|
| Price | $10.75 | $5.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $8.67 | $8.00 |
| AVG Volume (30 Days) | ★ 144.6K | 57.9K |
| Earning Date | 05-14-2026 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $150,545,364.00 | N/A |
| Revenue This Year | $14.41 | N/A |
| Revenue Next Year | $11.41 | N/A |
| P/E Ratio | $1,127.00 | ★ N/A |
| Revenue Growth | ★ 5.59 | N/A |
| 52 Week Low | $2.80 | $2.57 |
| 52 Week High | $12.25 | $6.75 |
| Indicator | WYY | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.27 | 55.42 |
| Support Level | $4.76 | $3.92 |
| Resistance Level | N/A | $5.55 |
| Average True Range (ATR) | 1.20 | 0.59 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 59.88 | 41.24 |
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.